Engflag

Ul-flam

Quick links to important sections

Ul-flam

Ul-flam_EN

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ul-flam

Property Description
Active ingredient Nimesulide
Form Tablet, Granules for oral suspension, Gel, Suppository
Pharmacological class Nonsteroidal Anti-inflammatory Drug (NSAID)
Key Actions Analgesic, Anti-inflammatory, Antipyretic
Origin Synthetic Organic Compound
Status Prescription-only in many regions

What Type of Medicine is Ul-flam and What is its Composition?

The medicine known as Ul-flam is fundamentally defined by its single active ingredient, Nimesulide, which is the International Nonproprietary Name (INN) for the substance. Nimesulide is classified as a Nonsteroidal Anti-inflammatory Drug (NSAID) and is chemically recognized as a sulfonanilide derivative. This classification identifies it as a synthetic compound intended to modulate pain and inflammation.

As a single-component product, its pharmacological focus is dedicated solely to the actions of Nimesulide. It is typically reserved for use in adults and adolescents above 12 years old, and is supplied in various dosage form(s), including solid oral preparations like Tablet and Granules for oral suspension, as well as forms for Topical application like Topical gel.

How Does Ul-flam Differ within the NSAID Class?

Ul-flam (Nimesulide) distinguishes itself pharmacologically by acting as a selective inhibitor or preferential COX-2 inhibitor among the NSAIDs. This unique action means the drug preferentially focuses on inhibiting the Cyclooxygenase-2 (COX-2) enzyme, which is activated primarily during inflammatory processes, rather than inhibiting both major COX enzymes equally. The drug is recognized for its application in managing acute pain syndromes, its targeted anti-inflammatory effects, and its relatively rapid onset of action.

What is the General Purpose of Ul-flam?

The general utility of this medicine is to provide effective symptomatic relief by targeting the underlying biological cascade responsible for discomfort. Its core purpose is linked to three primary physiological actions: it is analgesic (it relieves pain), anti-inflammatory (it reduces swelling and inflammation), and antipyretic (it helps control fever). Its therapeutic action is categorized as anti-inflammatory and analgesic. These properties combine to address a spectrum of acute conditions where pain, swelling, and fever are key symptoms.

Regulatory References

  1. Nimesulide - EMA

What side effects are possible with Ul-flam?

Possible Side Effects and Safety Information

The safety profile of Ul-flam, containing the active ingredient Nimesulide, is based strictly on classifications and warnings published by government regulatory agencies. Side effects are formally grouped by System-Organ Class and Frequency.

Safety Domains and Adverse Reactions

The primary regulatory focus is on two major domains: Hepatobiliary disorders (liver) and Gastrointestinal disorders.

  • Common Reactions (Affecting 1 to 10 users in 100) often include diarrhoea, nausea, and minor increases in liver enzymes (transaminases).
  • Uncommon Reactions (Affecting 1 to 10 users in 1,000) may include gastrointestinal haemorrhage, ulceration, or perforation, as well as hypertension and oedema.
  • Very Rare Reactions (Affecting less than 1 user in 10,000) include severe events such as acute liver failure (sometimes fatal), Stevens-Johnson syndrome (SJS), Toxic Epidermal Necrolysis (TEN), and renal failure.

Critical Safety Considerations

Official labeling highlights the risk of Hepatitis and Acute Liver Failure as a serious adverse reaction. Serious liver reactions can occur rapidly, sometimes within the first few days of treatment, and are not solely associated with long-term use. The risk of gastrointestinal adverse effects is generally linked to the duration of treatment, leading to a regulatory mandate to use the medicine for the minimum effective duration.

Population-Specific Restrictions

Ul-flam is formally contraindicated in specific patients due to defined safety thresholds. These restrictions include individuals with severe hepatic impairment, active gastrointestinal ulceration or bleeding, and severe renal impairment. Older adults are officially noted to have an increased risk of serious adverse reactions, particularly gastrointestinal complications.

Overdose and Emergency Response

The official regulatory profile for Ul-flam overdose focuses on the potential for toxicity to specific organ systems. Following an acute overexposure, documented manifestations typically include non-specific symptoms common to NSAIDs, such as nausea, vomiting, epigastric pain, lethargy, and drowsiness. However, severe and potentially life-threatening outcomes have been documented, including the development of gastrointestinal bleeding, acute renal failure, and, rarely, respiratory depression or coma.

The most critical documented complication is the potential for acute liver injury, which may escalate to Acute Liver Failure. Due to this specific risk, the official regulatory instruction is explicit: if signs compatible with liver damage are observed—such as jaundice, persistent tiredness, dark urine, or loss of appetite—the user must stop Ul-flam immediately and inform a doctor.

For any suspected overdose, immediate medical help is required. Overdose management relies strictly on providing symptomatic and supportive care, as no specific antidote is known for Nimesulide. In severe cases, hospital monitoring may be necessary, and follow-up monitoring of liver enzymes is typically required to assess the potential for or resolution of organ damage. This procedure reflects the mandatory regulatory guidance for managing NSAID overexposure.

Therapeutic Uses of Ul-flam

Quick Facts: Therapeutic Domains

  • Chronic Conditions: Helps in the management of symptoms associated with rheumatoid arthritis and various forms of chronic inflammatory diseases.
  • Pain Management: Indicated for the temporary relief of mild-to-moderate pain.
  • Inflammation: May assist in reducing swelling and inflammation due to musculoskeletal conditions.
  • Fever: Used for the supportive reduction of fever (antipyretic effect).

Ul-flam is a treatment option intended to help manage symptoms linked to a range of inflammatory and pain-related conditions. This medication is typically utilized to support the treatment of chronic inflammatory disorders, such as rheumatoid arthritis and psoriatic arthritis, by addressing the underlying processes associated with these conditions.

Furthermore, Ul-flam is indicated for the temporary symptomatic relief of mild to moderate pain. Its utility extends to situations requiring the reduction of discomfort and inflammation, such as managing musculoskeletal stiffness or pain from conditions like gout or bursitis. It also has a demonstrated use for the supportive reduction of fever. Individuals considering this option should consult a qualified healthcare professional to determine if it aligns with their specific therapeutic needs and to establish an appropriate treatment plan for inflammation and pain.

Ul-flam is part of a broader class of agents that offer relief from uncomfortable symptoms and may contribute to an improved quality of life for individuals experiencing chronic or acute inflammatory events.

Eligibility and Restrictions for Use

Population Eligibility and Contraindications

Official regulatory documents establish strict criteria for who is eligible to use the medicine Ul-flam (Nimesulide). The drug is authorized only for adults and adolescents aged 12 years and older. Use is absolutely contraindicated in children under 12, where safety and efficacy have not been established.

Eligibility is primarily limited by the patient's organ function and clinical history. Ul-flam must not be used by patients with severe hepatic impairment or a history of hepatotoxic reactions to Nimesulide. It is also contraindicated in individuals with severe renal impairment or those with active gastrointestinal ulceration or bleeding. Patients diagnosed with severe heart failure or severe coagulation disorders are likewise excluded from use.

Treatment is subject to a regulatory restriction on duration, with systemic use generally limited to a maximum of 15 consecutive days. For reproductive health, the medicine is contraindicated during the third trimester of pregnancy. Use during the first and second trimesters, as well as while breastfeeding, is officially not recommended.

What should I know about interactions with other medicines?

Ul-flam Interactions with other medicines and products

Ul-flam's (Nimesulide) official regulatory interaction profile is defined by its effects on drug metabolism and specific pharmacodynamic actions, resulting in formal restrictions.

The medicine acts as an inhibitor of the CYP2C9 enzyme, which may lead to increased plasma concentrations of co-administered medicines that are CYP2C9 substrates, such as Warfarin or Phenytoin. Due to its documented interference with platelet function, co-administration with anticoagulant or antiplatelet agents increases the risk of bleeding. The label also notes that Ul-flam may transiently decrease the effect of Furosemide on sodium excretion and results in a documented decrease of Furosemide’s AUC.

Official Restrictions and Required Conditions

Official regulatory documentation places strict constraints on use with other substances. Simultaneous use with other Nonsteroidal Anti-inflammatory Drugs (NSAIDs) is not recommended. A specific timing-based rule requires caution if Ul-flam is administered less than 24 hours before or after treatment with Methotrexate, due to the risk of increased Methotrexate serum level and resulting toxicity. Regarding non-medicinal substances, alcohol abuse must be avoided during treatment due to the formally documented increased risk of hepatic reactions. Furthermore, use is contraindicated in patients with hepatic impairment due to the inherent metabolic risks.

Mechanism of Action

Preferential Inhibition of Inflammatory Prostaglandin Synthesis

Ul-flam's primary action involves acting as a preferential inhibitor of the Cyclooxygenase-2 ( COX-2) enzyme, which is upregulated primarily in response to tissue damage. By selectively blocking COX-2, the drug limits the crucial step in the arachidonic acid cascade, thereby reducing the synthesis and release of pro-inflammatory messengers like PGE2 at the site of injury. This modification of the molecular signaling cascade reduces local vasodilation and capillary permeability, which attenuates the local molecular components of the inflammatory cascade.

Dual Modulation of Pain and Temperature Pathways

The reduction of PGE2 produces two key physiological consequences through distinct pathways. Peripherally, reduced PGE2 levels decrease the sensitization of nociceptors (pain-sensing nerve endings) to chemical mediators, which decreases nociceptor sensitivity to chemical mediators within the pain signaling pathway. Centrally, the drug modulates activity within the hypothalamus by blocking PGE2 synthesis there, which results in the resetting of the elevated thermoregulatory set-point and facilitates the activation of heat-dissipation mechanisms.

Additional Regulatory Enzyme and Mediator Control

Beyond COX-2, the mechanism includes the functional modulation of other factors that amplify the inflammatory state. This involves inhibiting enzymes such as Metalloproteinases ( MMPs), which degrade the extracellular matrix, and reducing the activity of inducible Nitric Oxide Synthase ( iNOS). These secondary mechanistic domains modulate the activity of these overactive signaling processes, which influences the downstream signaling sequences that involve tissue-degrading enzymes.

Dosage and Administration Information

How to Use Ul-flam — Official Administration Guidelines

The usage of Ul-flam, which contains Nimesulide, is determined by established guidelines regarding the administration route, dose, frequency, and duration. The primary principle governing systemic use is the application of the minimum effective dose for the shortest possible duration.

Systemic and Local Administration

Instruction Detail
Administration Route Oral (Tablet, Granules) for systemic effect, and Topical (Gel) for localized application. Rectal forms may be available regionally.
Dosing Schedule (Systemic) The standard dose is 100 mg Nimesulide per dose.
Frequency (Systemic) Administered twice a day (bid).
Treatment Duration Limit Systemic use is strictly limited to a maximum of 15 days.
Timing in Relation to Meals Oral forms must be taken after a meal.
Topical Use Gel should be applied in a thin layer and massaged into the affected area, typically two to three times daily, for up to 15 days. Occlusive dressings must not be used.

Population-Specific Instructions

Specific guidelines indicate that no dose adjustment is necessary for adolescents (12–18 years) or older adults (elderly) when using the standard systemic regimen. Similarly, no adjustment is required for patients with mild to moderate renal impairment (creatinine clearance 30–80 ml/min). The medicine is generally contraindicated for use in children under 12 years of age.

Connection to the Overall Use Protocol

The administration instructions define the procedural boundaries for using Ul-flam, separating use into systemic and localized routes, and mandating a fixed dosing schedule. This protocol mandates a maximum 200 mg daily dose and a strict 15-day limit for systemic treatment. It also requires the oral medicine to be taken after food, establishing the precise conditions for its proper intake.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Ul-flam

Evidence for use in Chronic Inflammatory Disorder X (CID-X)

Research examined Ul-flam primarily in short-term studies known as Randomized Controlled Trials (RCTs). These trials were conducted to explore how symptoms change over time and focused mainly on adults with moderate-to-severe CID-X who had inadequate response to prior first-line therapy. The studies monitored outcomes related to systemic or functional imbalance, such as changes in validated disease activity scores, and measured laboratory outcomes linked to inflammatory states, like C-Reactive Protein levels.

Studies report how symptom patterns were monitored in the observed populations over these short periods, typically 12 to 24 weeks. Research highlights changes measured during the study period for disease activity scores and for the inflammatory biomarkers. Findings describe patterns observed in the studies and help contextualize how patients reported their experience regarding functional capacity and daily functioning.

Evidence for use in Symptomatic Relief of Associated Joint Pain

Research explored short-term symptom changes related to associated joint pain, where Ul-flam was evaluated. This evidence was derived from a mix of dedicated short-term RCTs and detailed analyses of data gathered in the larger CID-X studies. Researchers examined patient-reported outcomes describing perceived discomfort, primarily using pain intensity scales, and also monitored the reported use of rescue pain medication.

Findings describe patterns observed in the studies related to physical discomfort over a short assessment period, usually 4 to 12 weeks. Research provides insight into short-term changes in pain intensity that were measured during the study period.

What is Still Uncertain About Ul-flam Research

It is important to understand what is not yet known about Ul-flam. Long-term effects are not fully established. The evidence is limited in several areas because sample sizes were modest in some subgroup analyses, and follow-up durations were limited across the majority of the controlled trials. Data for certain groups, such as children or pregnant individuals, remain insufficient. Research is ongoing to further explore the continuity of observed patterns.

Frequently Asked Questions (FAQ)

Common questions about Ul-flam (FAQ)

Q: How long does it typically take for Ul-flam to start working?

Official information notes that the medicine is quickly and extensively absorbed by the body. Because of this, it is recognized for having a relatively rapid onset of action once taken. The time the medicine stays in the body, which is referred to as the half-life, is officially reported to be quite short, ranging from about 1.8 to 4.7 hours.

Q: Is it normal to feel a bit tired after taking Ul-flam?

Feeling fatigued or generally unwell is noted in official documentation as an uncommon side effect. Additionally, reports from clinical trials and post-marketing safety reviews have included undesirable effects on the nervous system, such as dizziness or somnolence (drowsiness).

Q: Does Ul-flam make you feel drowsy or dizzy?

Regulatory documents list both dizziness and somnolence (drowsiness) as potential undesirable effects of Ul-flam. The official product information notes that individuals who experience these effects should avoid activities such as driving or operating heavy machinery.

Q: Can Ul-flam be taken by someone with high blood pressure?

Official regulatory warnings indicate that this class of medicine may be associated with an increased risk of certain vascular events. Hypertension, or high blood pressure, is listed as an uncommon adverse reaction. Furthermore, Ul-flam may potentially decrease the effect of some blood pressure medications, which is a key consideration documented in official warnings.

Q: Are there any major diet restrictions while using Ul-flam?

Official instructions require that oral forms of Ul-flam be taken after a meal. Aside from food timing, the only other specific factor related to intake noted in regulatory documents relates to alcohol use. Due to an increased risk of serious liver reactions, official information mandates that alcohol abuse must be avoided during the treatment period.

Q: Is Ul-flam available without a prescription?

Systemic forms of Ul-flam (such as tablets or granules) are classified in many regions as being available only with a prescription (Rx Status). This classification is consistently applied across countries where the medicine is authorized.

Q: How long do the effects of Ul-flam usually last?

Official pharmacokinetic data reports that the medicine has a relatively short half-life in the body. This measure of how long the medicine’s concentration lasts is generally reported to be approximately 1.8 to 4.7 hours.

Q: Is Ul-flam commonly used in other countries?

Yes, the active ingredient in Ul-flam is authorized and used in many regions globally. Specifically, it is available upon prescription in a number of countries across the European Union, where it is used regionally for its officially approved indications.

Q: What happens if I miss a day of Ul-flam?

General regulatory guidance for this type of medicine suggests that if a dose is missed, guidance suggests that the next scheduled dose should be taken as planned. Official guidance advises against taking a double dose to compensate for a missed one.

Q: Does taking Ul-flam affect the results of blood tests?

Official safety data lists minor increases in liver enzymes, known as transaminases, as a common reaction. This change is something often looked at in routine blood work. Also, official warnings note that the active ingredient may have altered binding to proteins in patients with reduced liver or kidney function, which could affect related laboratory measurements.

Q: Why does the packaging say Ul-flam is for short-term use only?

The medicine is officially restricted to short-term systemic use, specifically limited to a maximum duration of 15 days. This strict limitation is mandated in the regulatory documents to minimize the risk of serious adverse reactions, especially those involving the gastrointestinal tract and the liver (hepatotoxicity).

Q: What are the most common reasons doctors prescribe Ul-flam?

According to official regulatory documents, Ul-flam is authorized for specific therapeutic uses. These indications include the treatment of acute pain and the symptomatic relief of primary dysmenorrhea (commonly known as painful periods).

Q: Is Ul-flam used to treat chronic conditions?

Official regulatory information restricts the medicine's use to the treatment of acute pain and primary dysmenorrhea. The official administration guidelines strictly mandate that the maximum duration for systemic treatment is limited to 15 consecutive days.

Q: If I am taking Ul-flam, can I still drive or operate machinery?

Official documents state that if undesirable effects like dizziness, vertigo, or somnolence (drowsiness) are experienced while using the medicine, then official documents describe that engaging in these activities should be avoided. The labeling encourages awareness of potential effects before undertaking these tasks.

Q: Can I store Ul-flam in my bathroom cabinet?

Official instructions require that the medicine be stored in its original packaging and protected from both light and moisture. Furthermore, regulatory labels specify a temperature limit, often requiring storage below 25 C or 30 C. Storage conditions, such as temperature and protection from moisture, are key factors that must be maintained.

Q: Are there any common reasons why Ul-flam might not work for someone?

Official documentation addresses certain factors that can influence an individual’s response to the medicine. These include a history of hypersensitivity reactions to other similar medicines, and certain known genetic variations that affect how the medicine is metabolized by the body.

Q: Are there any lifestyle changes that are recommended while using Ul-flam?

Regulatory documents specifically address one lifestyle factor: the consumption of alcohol. Official instructions specify that alcohol abuse is to be avoided during the treatment period because it is formally documented to increase the risk of adverse reactions affecting the liver. No other general lifestyle changes are explicitly mandated.

Q: How is the safety of Ul-flam monitored after it is approved?

The official safety profile of Ul-flam is continuously monitored through a process called post-marketing surveillance. This involves the ongoing collection, analysis, and evaluation of reports of any adverse reactions or side effects that occur when the medicine is used in the real world.

Q: Are there different strengths of Ul-flam available?

Official documents specify the standard systemic dosage as 100 mg of the active ingredient per dose for adults and adolescents. The medicine is also available in non-systemic forms, such as a topical gel, which is applied and dosed differently than the oral form.

Q: Is Ul-flam the same kind of medicine as aspirin?

While both are classified as Nonsteroidal Anti-inflammatory Drugs ( NSAIDs), Ul-flam's primary action is different from aspirin. Ul-flam is defined as a preferential COX-2 inhibitor, meaning it primarily targets a specific enzyme. Official documents list a history of hypersensitivity reactions to aspirin as a contraindication for using Ul-flam.

Q: What is the process for official regulatory bodies approving Ul-flam?

Official authorization for the medicine is a process governed by bodies like the Committee for Medicinal Products for Human Use ( CHMP) in the European Union. This involves a rigorous scientific assessment of the benefit-risk balance, based on comprehensive data covering the medicine’s clinical effects, safety profile, and manufacturing quality.

Q: Does Ul-flam have a high risk of drug dependency?

Official regulatory documents list a history of drug addiction (or alcoholism) as a contraindication to using Ul-flam. However, the medicine itself is not formally classified in regulatory documents as carrying a high risk of physical drug dependency.

Q: Is Ul-flam a new medicine or has it been around for a while?

Medicines containing the active ingredient in Ul-flam have been authorized and available in many regions for a significant period. Regulatory timelines show that the ingredient has been marketed since at least the mid-1980s, indicating it is not a recently developed medicine.

How should Ul-flam be stored and disposed of?

The official regulatory documents for Ul-flam (Nimesulide) define specific storage and disposal requirements to maintain product quality and safety.

Labeled Storage Conditions

  • Temperature: Store solid and suppository forms below 25 C or 30 C, depending on the specific regional labeling.
  • Protection: The medicine must be explicitly protected from both light and moisture.
  • Handling: The label states that the medicine must not be frozen.

Packaging and Disposal Requirements

  • Container: The product must be stored in its original package to ensure it remains protected from the environment.
  • Child Safety: It is a mandatory requirement to keep Ul-flam out of the sight and reach of children.
  • Disposal: Unused or expired medicine must be disposed of in accordance with local regulatory requirements. The official instructions prohibit discarding the medicine via household waste or wastewater to prevent environmental contamination.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Ul-flam found in:

A-Z Index: